Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Qize Ding Analyst Performance

Analyst at Rothschild & Co Redburn

Qize Ding is a stock analyst at Rothschild & Co Redburn in the medical sector, covering 4 publicly traded companies. Over the past year, Qize Ding has issued 5 stock ratings, including buy and hold recommendations. While full access to Qize Ding's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Qize Ding's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
60.00% 3 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy60.0%3 ratings
Hold40.0%2 ratings
Sell0.0%0 ratings

Out of 5 total stock ratings issued by Qize Ding at Rothschild & Co Redburn, the majority (60.0%) have been Buy recommendations, followed by 40.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Qize Ding, an analyst at Rothschild & Co Redburn, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Qize Ding of Rothschild & Co Redburn specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
100.0%

Qize Ding's Ratings History at Rothschild & Co Redburn

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
5/1/2026Initiated Coverage$82.89$140.00Buy
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
5/1/2026Initiated Coverage$80.75$140.00Buy
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
3/19/2026Upgrade$16.23$40.00Buy
Arcellx, Inc. stock logo
ACLX
Arcellx
2/12/2026Downgrade$69.88$82.00Neutral
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2/12/2026Downgrade$18.54$24.00Neutral